23:31 , Dec 12, 2018 |  BC Extra  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest inhibiting STAT3 or immune checkpoint inhibitors could help treat idiopathic pulmonary fibrosis (IPF) or sarcoidosis-associated pulmonary fibrosis. In IPF patients, lung levels of PD-1...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on P2RX7 could help predict outcomes in heart transplant patients. In 102 heart transplant patients, P2RX7 genotyping identified an association between a SNP on P2RX7 (rs3751143) and the risk of rapidly...
17:55 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture, mouse, rat and dog studies identified a RORγT inverse agonist that could help treat inflammation. Chemical synthesis and screening of a subset of Pfizer Inc.’s small compound library in a HEK-cell...
21:45 , Apr 19, 2018 |  BC Extra  |  Company News

Novartis reports first Kymriah sales, Cosentyx miss

Novartis AG (NYSE:NVS; SIX:NOVN) reported $580 million in 1Q18 sales of autoimmune drug Cosentyx secukinumab, shy of analysts' $635 million consensus estimate. The pharma also reported for the first time sales of CAR T therapy...
15:46 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to express IL-7 and CCL19 could enhance the efficacy of T cell therapies for cancer. The method involves engineering solid tumor antigen-targeting CAR T cells, dubbed proliferation-inducing and...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); pain Mouse studies suggest inhibiting CAMK2A could help treat MS, including MS-associated pain. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, knock-in of an autophosphorylation-deficient CAMK2A variant or intrathecal...